Simultaneous Determination Of Probenecid And Sulopenem Etzadroxil Using RP-UPLC With Pda Detector

Abstract

Objective: The present study aimed to verify the cancer healing medications (Probenecid and Sulopenem Etzadroxil) by means of a UPLC (Waters Acquity) apparatus that had a PDA detector, and to separate them.

Methods: The isocratic RP-UPLC technique for the quantitative measurement of Probenecid and Sulopenem Etzadroxil is characterized by its simplicity, selectivity, validation, and well-defined stability. The Acquity UPLC BEH chemistry Shield RP-18 column, with dimensions 50x2.1 mm and 1.7 micron, was used in the chromatographic technique. The mobile phase consisted of a mixture of acetonitrile and 0.1% perchloric acid (30+70). The elution method was isocratic. Using the PDA detector, the instrumental parameters were adjusted at a 272 nm wavelength and a flow rate of 0.2 ml/min.

Results: Sulopenem Etzadroxil had a limit of detection (LOD) of 0.5 µg/ml and a limit of quantification (LOQ) of 2.0 µg/ml, whereas Probenecid had limits of 0.5 µg/ml and 2.0 µg/ml. An R2 value greater than 0.999 indicates that the calibration charts were linear. While validating the technique, we checked its recovery, specificity, linearity, accuracy, robustness, and ruggedness, and all were within acceptable ranges. We followed the rules set forth by the International Conference on Harmonization (ICH) when we validated the suggested technique.

Conclusion: In an experimental setting, the suggested approach should work quickly, easily, practically, and cheaply. It has several applications in stability testing, including regular examination of industrial samples and medication sample quality verification.